1. Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353: 2121-34

2. Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartII JP Després, N Engl J Med 2005; 353: 2121-34

3. Changes from Baseline for the Efficacy and Safety End Points in the Intention-to-Treat Population, According to the Repeated-Measures (RM) Method and Last-Observation-Carried-Forward (LOCF)Analyses – Part I JP Després, N Engl J Med 2005; 353: 2121-34

4. Changes from Baseline for the Efficacy and Safety End Points in the Intention-to-Treat Population, According to the Repeated-Measures (RM) Method and Last-Observation-Carried-Forward (LOCF)Analyses – Part II JP Després, N Engl J Med 2005; 353: 2121-34

5. Effect of Placebo or Rimonabant for 52 Weeks on Body Weight, Waist Circumference, Plasma Triglyceride Levels, and High-Density Lipoprotein (HDL) Cholesterol Levels JP Després, N Engl J Med 2005; 353: 2121-34

6. Effect of Placebo or 20 mg of Rimonabant for 52 Weeks on the Plasma Glucose and Insulin Responses to Oral Glucose Challenge (Panels A - B), and the Plasma Adiponectin Level (Panels C - D) JP Després, N Engl J Med 2005; 353: 2121-34

7. Adverse Events – Part I JP Després, N Engl J Med 2005; 353: 2121-34

8. Adverse Events – Part II JP Després, N Engl J Med 2005; 353: 2121-34